Jani AB, Schreibmann E, Goyal S, et al. - Given a growing use of molecular imaging to guide treatment decisions and planning in prostate cancer, researchers assessed the role of ¹⁸ F-fluciclovine-PET/CT in improving cancer control vs conventional imaging (bone scan and either CT or MRI) alone for salvage postprostatectomy radiotherapy. Patients suffering from prostate cancer with identifiable PSA post-prostatectomy and negative conventional imaging (no extrapelvic or bone findings) were enrolled in a single-centre, open-label, phase 2/3 randomised controlled trial (EMPIRE-1) and were randomized in a 1:1 ratio to radiotherapy directed by conventional imaging alone or to conventional imaging plus ¹⁸ F-fluciclovine-PET/CT. Findings showed that a significant improvement in survival free from biochemical recurrence or persistence was achieved as a consequence of inclusion of ¹⁸ F-fluciclovine-PET into postprostatectomy radiotherapy decision making and planning. Combination of novel PET radiotracers into radiotherapy decisions as well as planning for prostate cancer patients requires further inquiry.